Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Linerixibat. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC10A2 known ✓ | Q12908 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Linerixibat SCHEMBL2579144 | 1.00 | SLC10A2 (1.00) | SLC10A2 | |
| Linerixibat SCHEMBL29429786 | 1.00 | SLC10A2 (1.00) | SLC10A2 | |
| Linerixibat SCHEMBL2584943 | 1.00 | SLC10A2 (1.00) | SLC10A2 | |
| SCHEMBL26226892 | 0.97 | SLC10A2 (0.94) | SLC10A2 | |
| SCHEMBL22360124 | 0.97 | SLC10A2 (0.94) | SLC10A2 | |
| SCHEMBL2591812 | 0.97 | SLC10A2 (1.00) | SLC10A2 | |
| SCHEMBL2590845 | 0.95 | SLC10A2 (0.90) | SLC10A2 | |
| SCHEMBL2592666 | 0.95 | SLC10A2 (0.90) | SLC10A2 | |
| SCHEMBL2590143 | 0.95 | SLC10A2 (0.90) | SLC10A2 | |
| SCHEMBL12176709 | 0.94 | SLC10A2 (1.00) | SLC10A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 418 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4724071-A1 | NOVEL USE OF AN ILEAL BILE ACID TRANSPORTER INHIBITOR FOR THE TREATMENT OF PRURITUS | GlaxoSmithKline Intellectual Property (No. 2) Limited (GB) | 2026-04-15 | — | — | EP | claimed |
| EP-4629997-A1 | ASBT INHIBITORS IN THE TREATMENT OF RENAL DISEASES | Albireo AB (SE) | 2025-10-15 | — | — | EP | claimed |
| EP-4590314-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS | Astellas Gene Therapies, Inc. (US) | 2025-07-30 | — | — | EP | claimed |
| WO-2025078973-A1 | SOLID STATE FORMS OF LINERIXIBAT AND PROCESS FOR PREPARATION THEREOF | ASSIA CHEMICAL INDUSTRIES LTD. (IL) | 2025-04-17 | — | — | WO | claimed |
| EP-4511038-A1 | SUBCUTANEOUS ADMINISTRATION OF AN ASBT INHIBITOR | Albireo AB (SE) | 2025-02-26 | — | — | EP | claimed |
| WO-2024251739-A1 | NOVEL USE OF AN ILEAL BILE ACID TRANSPORTER INHIBITOR FOR THE TREATMENT OF PRURITUS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2024-12-12 | — | — | WO | claimed |
| US-20240408186-A1 | TREATMENT OF PRIMARY BILIARY CHOLANGITIS (PBC) WITH TOLERIZING NANOPARTICLES | COUR PHARMACEUTICALS DEVELOPMENT COMPANY INC. | 2024-12-12 | — | — | US | claimed |
| US-20240391885-A1 | FORMS OF LINERIXIBAT | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2024-11-28 | — | — | US | claimed |
| US-20240366785-A1 | COMPOSITIONS AND METHODS FOR IMPROVED TREATMENT OF X-LINKED MYOTUBULAR MYOPATHY | AUDENTES THERAPEUTICS INC (US) | 2024-11-07 | — | — | US | claimed |
| EP-4422632-A1 | APICAL SODIUM-DEPENDENT TRANSPORTER INHIBITOR COMPOSITIONS | Mirum Pharmaceuticals, Inc. (US) | 2024-09-04 | — | — | EP | claimed |
| EP-4232448-A1 | AGONISTS OF FREE FATTY ACID RECEPTOR 1 AND THEIR USE IN DISEASES ASSOCIATED WITH SAID RECEPTOR | Halo Therapeutics Ltd (GB) | 2023-08-30 | — | — | EP | claimed |
| WO-2023076260-A1 | APICAL SODIUM-DEPENDENT TRANSPORTER INHIBITOR COMPOSITIONS | MIRUM PHARMACEUTICALS, INC. (US) | 2023-05-04 | — | — | WO | claimed |
| WO-2023070104-A1 | TREATMENT OF PRIMARY BILIARY CHOLANGITIS (PBC) WITH TOLERIZING NANOPARTICLES | COUR PHARMACEUTICALS DEVELOPMENT COMPANY INC. (US) | 2023-04-27 | — | — | WO | claimed |
| WO-2022251208-A1 | COMPOSITIONS AND METHODS FOR IMPROVED TREATMENT OF X-LINKED MYOTUBULAR MYOPATHY | AUDENTES THERAPEUTICS, INC. (US) | 2022-12-01 | — | — | WO | claimed |
| US-20220160726-A1 | METHODS FOR TREATING CHOLESTASIS | MIRUM PHARMACEUTICALS, INC. (US) | 2022-05-26 | — | — | US | claimed |
| US-20220133738-A1 | GENOTYPE AND DOSE-DEPENDENT RESPONSE TO AN ASBTI IN PATIENTS WITH BILE SALT EXPORT PUMP DEFICIENCY | MIRUM PHARMACEUTICALS, INC. (US) | 2022-05-05 | — | — | US | claimed |
| WO-2022083853-A1 | AGONISTS OF FREE FATTY ACID RECEPTOR 1 AND THEIR USE IN DISEASES ASSOCIATED WITH SAID RECEPTOR | GBIOTECH S.À.R.L. (CH) | 2022-04-28 | — | — | WO | claimed |
| CN-114096268-A | Methods for increasing growth in pediatric subjects with cholestatic liver disease | 米鲁姆制药公司 | 2022-02-25 | — | — | CN | claimed |
| US-20220055999-A1 | SYNTHETIC METHODS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2022-02-24 | — | — | US | claimed |
| CN-114072153-A | Methods for treating cholestasis | 米鲁姆制药公司 | 2022-02-18 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240366785-A1 | COMPOSITIONS AND METHODS FOR IMPROVED TREATMENT OF X-LINKED MYOTUBULAR MYOPATHY | CKMT1A; CKMT1B, PYGM, CPT1B | SLC10A2 134/4885 |
| US-20240391885-A1 | FORMS OF LINERIXIBAT | PYGL, DCXR, CYP2C9 | SLC10A2 44/4885 |
| US-20220055999-A1 | SYNTHETIC METHODS | SLC10A1, GYS2, CYP7A1 | SLC10A2 21/4885 |
| US-20220133738-A1 | GENOTYPE AND DOSE-DEPENDENT RESPONSE TO AN ASBTI IN PATIENTS WITH BILE SALT EXPORT PUMP DEFICIENCY | SLC10A1, ABCB11, SLC10A2 | SLC10A2 3/4885 |
| US-20220160726-A1 | METHODS FOR TREATING CHOLESTASIS | SLC10A1, SLC10A2, NR1H4 | SLC10A2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.